Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis

D’Incà, R.; Brambatti, Michela; Scarpa, Marco; Grillo, A.; Brun, Paola; Vettorato, Maria Grazia; Castagliuolo, Ignazio; Sturniolo, Giacomo Carlo

doi:10.1007/s10620-010-1384-1

Cited by 74 publications

(44 citation statements)

References 47 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLRs first recognize the pathogen associated molecular patterns (PAMPs) and trigger a series of cascades to activate nuclear factor-κB and mitogen activated protein kinase P38, which subsequently induce the release of various cytokines, including IL-6, IL-1, IL-8, IL-10, IL-12, TNF-α, nitric oxide synthase, and B7 molecules. Thus, TLRs aggravate inflammatory reactions (23,24). Haller et al (25) has reported that peptidoglycans and lipopolysaccharides of bacteria may act as PAMPs to interact with TLR2 and TLR4, respectively.…”

Section: Discussionmentioning

confidence: 99%

Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid

Yao

Tan

Gao

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study aimed to investigate the regulatory effect of probiotics on the expression of Toll-like receptors (TLRs) in an ulcerative colitis (UC) rat model, and to determine the role of probiotics in the underlying mechanisms through which UC develops and progresses in rat models. Rats were randomly allocated to one of the four following groups: i) The healthy control, ii) the model, iii) the Golden bifid treatment group, and iv) the TLR4 monoclonal antibody (TLR4mAb) intervention group. The UC rat model was established using 2,4,6-trinitro-benzene sulfonic acid. The general status and histological changes of rats were scored using the disease activity index and the histopathological scoring method, respectively. In these rats, the expression of TLR4 and TLR2 was measured using reverse transcription-quantitative polymerase chain reaction. The expression of TLR4 and TLR2 in the model group was significantly higher than that in the healthy control group. However, when compared with the model rats, those that received either Golden bifid treatment or TLR4mAb intervention exhibited significantly decreased mRNA expression levels of TLR4 and TLR2 (P<0.05). The development of UC is characterized by an abnormal immune response in the intestines. Probiotics alleviated inflammatory reactions in rats with UC. The underlying mechanism of UC may be associated with the expression of TLRs and the subsequent release of inflammatory cytokines.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid

Yao

Tan

Gao

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…In addition, this approach remarkably reduced the levels of TLR-4 and IL-1β mRNA while increasing mucosal IL-10. Accordingly, modification of mucosal microbiota by L. casei DG and its impacts on the mucosal immunity seem to be critical for the favorable roles of this probiotics in ulcerative colitis patients [128]. …”

Section: Reviewmentioning

confidence: 99%

Role of intestinal microbiota and metabolites on gut homeostasis and human diseases

2017

View full text Add to dashboard Cite

BackgroundA vast diversity of microbes colonizes in the human gastrointestinal tract, referred to intestinal microbiota. Microbiota and products thereof are indispensable for shaping the development and function of host innate immune system, thereby exerting multifaceted impacts in gut health.MethodsThis paper reviews the effects on immunity of gut microbe-derived nucleic acids, and gut microbial metabolites, as well as the involvement of commensals in the gut homeostasis. We focus on the recent findings with an intention to illuminate the mechanisms by which the microbiota and products thereof are interacting with host immunity, as well as to scrutinize imbalanced gut microbiota (dysbiosis) which lead to autoimmune disorders including inflammatory bowel disease (IBD), Type 1 diabetes (T1D) and systemic immune syndromes such as rheumatoid arthritis (RA).ResultsIn addition to their well-recognized benefits in the gut such as occupation of ecological niches and competition with pathogens, commensal bacteria have been shown to strengthen the gut barrier and to exert immunomodulatory actions within the gut and beyond. It has been realized that impaired intestinal microbiota not only contribute to gut diseases but also are inextricably linked to metabolic disorders and even brain dysfunction.ConclusionsA better understanding of the mutual interactions of the microbiota and host immune system, would shed light on our endeavors of disease prevention and broaden the path to our discovery of immune intervention targets for disease treatment.

show abstract

“…d'incà et al (ref. 37 ) evaluated the effect of an 8-week oral and/or rectal administration of lactobacillus casei dG on colonic-associated microbiota, mucosal cytokine balance, and Tlr expression in patients with mild left-sided Uc. The patients were divided into three groups: the first group received oral 5-asa alone, the second group received oral 5-asa plus oral lactobacillus casei dG (8 × 108 cFU), and the third group received oral 5-asa and rectal lactobacillus casei dG (8 × 108 cFU).…”

Section: Discussionmentioning

confidence: 99%

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Palumbo¹,

Romeo²,

Gammazza³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aim.Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

show abstract

Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis

Abstract: Manipulation of mucosal microbiota by L. casei DG and its effects on the mucosal immune system seem to be required to mediate the beneficial activities of probiotics in UC patients.

Cited by 74 publications

References 47 publications

Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid

Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid

Role of intestinal microbiota and metabolites on gut homeostasis and human diseases

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Contact Info

Product

Resources

About